NASDAQ:NBSE NeuBase Therapeutics (NBSE) Stock Price, News & Analysis $0.38 -0.01 (-3.20%) (As of 05/10/2024) Add Compare Share Share Today's Range$0.37▼$0.3950-Day Range$0.38▼$0.3852-Week Range$0.36▼$4.80Volume97,700 shsAverage Volume191,869 shsMarket Capitalization$1.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrends Get NeuBase Therapeutics alerts: Email Address Ad Capital TrendsMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukraine was used to cyberattacks. But the WhisperGate attack just before Russia's full-scale invasion was different. It was larger... and it was aimed at dismantling Ukraine's critical infrastructure. The company's unique expertise and scalable approach allowed them to nearly double revenues between 2021-2023, and they've added another $20 million in new sales orders this year alone. There is no denying - the opportunity here is massive.Click here to learn how a small company is joining the ranks of Lockheed Martin and Raytheon About NeuBase Therapeutics Stock (NASDAQ:NBSE)NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.Read More NBSE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBSE Stock News HeadlinesMay 13, 2024 | bizjournals.comNeuBase Therapeutics shareholder meeting adjourns without dissolution approvalMay 6, 2024 | bizjournals.comNeuBase Therapeutics to delist from Nasdaq next weekSeptember 16, 2024 | Weiss Ratings (Ad)Nvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.April 6, 2024 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from NasdaqApril 5, 2024 | globenewswire.comNeuBase Therapeutics Announces Receipt of Notice from NasdaqMarch 27, 2024 | msn.comWhy Neubase Therapeutics (NBSE) Shares Are NosedivingMarch 26, 2024 | msn.comNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversMarch 26, 2024 | investorplace.comWhy Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?September 16, 2024 | Weiss Ratings (Ad)Nvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.March 25, 2024 | bizjournals.comNeuBase Therapeutics sets shareholder meeting on dissolution planFebruary 26, 2024 | edition.cnn.comNeuBase Therapeutics IncFebruary 20, 2024 | finance.yahoo.comNeuBase Therapeutics, Inc. (NBSE)January 20, 2024 | ca.finance.yahoo.comNeuBase Therapeutics Inc (O7P.BE)December 22, 2023 | bizjournals.comCMU halts licensing agreement with NeuBase TherapeuticsNovember 27, 2023 | finance.yahoo.comPsychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNovember 6, 2023 | morningstar.comNeuBase Therapeutics Inc NBSEOctober 6, 2023 | finance.yahoo.comNeuBase Therapeutics, Inc. (NBSE.MX)September 12, 2023 | benzinga.comMassive Insider Trade At NeuBase TherapeuticsSee More Headlines Receive NBSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/23/2021Today9/15/2024Next Earnings (Estimated)9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NBSE CUSIPN/A CIK1173281 Webwww.neubasetherapeutics.com Phone(164) 645-1790FaxN/AEmployees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.04 per share Price / Book0.03Miscellaneous Outstanding Shares3,752,000Free Float3,456,000Market Cap$1.43 million OptionableNot Optionable Beta0.81 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Todd P. Branning (Age 54)Interim CEO, CFO & Secretary Comp: $427.44kDr. Dietrich A. Stephan Ph.D. (Age 54)Founder, President & Director Comp: $836.58kKey CompetitorsAptevo TherapeuticsNASDAQ:APVOAvalon GloboCareNASDAQ:ALBTBright Minds BiosciencesNASDAQ:DRUGBiomericaNASDAQ:BMRAChromocell TherapeuticsNYSE:CHROView All Competitors NBSE Stock Analysis - Frequently Asked Questions How have NBSE shares performed this year? NeuBase Therapeutics' stock was trading at $0.7401 at the beginning of 2024. Since then, NBSE stock has decreased by 48.7% and is now trading at $0.38. View the best growth stocks for 2024 here. How were NeuBase Therapeutics' earnings last quarter? NeuBase Therapeutics, Inc. (NASDAQ:NBSE) posted its earnings results on Thursday, December, 23rd. The company reported ($4.20) EPS for the quarter, topping analysts' consensus estimates of ($4.60) by $0.40. When did NeuBase Therapeutics' stock split? NeuBase Therapeutics's stock reverse split on Thursday, June 15th 2023. The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of NeuBase Therapeutics? Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NeuBase Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN) and Pfizer (PFE). This page (NASDAQ:NBSE) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Turn Smartphones Into “Earnphones”?High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportu...Mode Mobile | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuBase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuBase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.